Schomäcker K, Franke W G, Weiss S, Lindner L, Jantsch K, Shukla S K, Limouris G S
Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln.
Nuklearmedizin. 1993 Feb;32(1):27-33.
This work attempted to overcome the problem of unwanted bone radioactivity after injection of tumour-affine heavy-metal compounds (prototype 169Yb-citrate) by pre-application of stable yttrium- and calcium-compounds into tumour-bearing mice in doses of 1 mg metal/kg body weight. The pre-application of stable yttrium and calcium resulted in a smaller bone radioactivity. The most favourable results were achieved by injecting the metal salts simultaneously at or within 5 h before the 169Yb-citrate. On the other hand a strong radioactivity increase in the RES (liver and spleen) by a factor of 2 to 4 was observed after yttrium-preapplication.
这项工作试图通过以1毫克金属/千克体重的剂量向荷瘤小鼠预先施用稳定的钇和钙化合物，来克服注射肿瘤亲和性重金属化合物（原型169Yb - 柠檬酸盐）后 unwanted bone radioactivity 的问题。预先施用稳定的钇和钙导致骨放射性降低。在注射169Yb - 柠檬酸盐的同时或在其前5小时内同时注射金属盐可获得最有利的结果。另一方面，预先施用钇后观察到RES（肝脏和脾脏）中的放射性强烈增加了2至4倍。
